Shield Therapeutics (STX) Stock Statistics & Valuation Metrics

Shield Therapeutics has a market cap or net worth of £94.56M. The enterprise value is 146.49M .

Shield Therapeutics has 1,068,418,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shield Therapeutics’s return on equity (ROE) is 1.20 and return on invested capital (ROIC) is -68.36%.

The current PE Ratio of Shield Therapeutics is ―. Shield Therapeutics’s PEG ratio is 0.38.

In the last 12 months, Shield Therapeutics had revenue of 50.74M and earned -18.03M in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -17.49M and capital expenditures -24.12K, giving a free cash flow of -17.52M billion.

Shield Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Shield Therapeutics upcoming earnings date is Sep 3, 2026, TBA (Confirmed).

Shield Therapeutics as a current ratio of 0.90, with Debt / Equity ratio of -199.87%

In the past 12 months, Shield Therapeutics has paid 524.78K in taxes.

Shield Therapeutics EV to EBITDA ratio is -10.23, with an EV/FCF ratio of -11.93.

Shield Therapeutics has £11.63M in cash and marketable securities with £30.15M in debt, giving a net cash position of -£18.52M billion.

Gross margin is 43.89%, with operating margin of -20.29%, and net profit margin of -35.52%.

The average price target for Shield Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―